Simulations Plus (SLP) Stock Price, News & Analysis

Written before these shares stopped trading.

Simulations Plus, Inc. (Nasdaq: SLP) operates in the professional, scientific, and technical services sector, with a focus on computer systems design and specialized software for the biopharmaceutical industry. According to company disclosures and recent filings, Simulations Plus combines biosimulation software, cheminformatics, and consulting and contract research services to support drug discovery, development, clinical operations, regulatory submissions, and commercialization.

The company reports two primary operating segments: software and services. Software offerings include tools used in pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) modeling, as described in prior overviews, and a broader biosimulation suite highlighted in recent news. Services include consulting, contract research, medical communications, and simulation-enabled performance and intelligence solutions for biopharma clients.

Business focus and role in drug development

Simulations Plus describes itself in press releases as a global leader in model‑informed and AI‑accelerated drug development. Its biosimulation solutions integrate artificial intelligence and machine learning (AI/ML) with approaches such as physiologically based pharmacokinetics (PBPK), physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology (QSP/QST), and population PK/PD modeling. These capabilities are used to help clients accelerate the discovery, development, and commercialization of pharmaceuticals and other products through science‑based software and consulting solutions.

Company communications note that its technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide. Simulations Plus also highlights experience of more than 25 years serving clients globally in the biopharma sector, positioning its tools and services as part of workflows that span research, clinical trial operations, regulatory interactions, and commercial support.

Software platforms and AI‑enabled ecosystem

Recent news describes an integrated, AI‑enabled modeling ecosystem that connects multiple validated scientific engines. These include GastroPlus®, MonolixSuite®, ADMET Predictor®, and quantitative systems pharmacology/toxicology platforms. Company releases state that these tools support PBPK modeling to project human exposure and guide dose selection, mechanistic toxicity assessment, and population modeling to connect preclinical and clinical understanding.

Simulations Plus also refers to an AI‑orchestrated framework that enables multi‑engine workflows and guided decision support through AI copilots, grounded in validated methods. The company has discussed cloud deployment, interoperability, and AI‑driven workflows, including the use of cloud‑scale compute and AI‑assisted workflows to handle intensive modeling tasks and streamline complex processes across its product ecosystem.

Services, consulting, and medical communications

Beyond software licenses, Simulations Plus provides consulting and contract research services to the pharmaceutical industry. Company descriptions emphasize scientific services that support client workflows across the drug lifecycle, including model‑informed safety and toxicology, clinical pharmacokinetics, and related disciplines. The services segment also includes medical communications support for clinical and commercial drug development, as well as simulation‑enabled performance and intelligence offerings that help organizations interpret and apply model outputs.

Management commentary in recent financial releases notes growth in commercialization‑related offerings and medical communications services, alongside development projects. These services are presented as complementary to the company’s software platforms, allowing clients to access domain expertise and customized analyses in addition to tools.

Revenue mix and operating structure

Financial disclosures show that Simulations Plus generates revenue from its software and services segments, with both contributing meaningful portions of total revenue. Company releases describe the software segment as a significant share of revenue, with services also representing a substantial and growing component. Geographic disclosures in prior descriptions indicate that a large portion of revenue has been earned in the United States, followed by EMEA and Asia Pacific.

Recent communications discuss a transition to a functionally driven operating model, with an emphasis on product and technology integration, cloud and AI strategy, and cost structure alignment. The company has also referenced a Corporate Development Initiative designed to support early‑stage technology companies in the pharmaceutical industry through minority investments that complement its organic growth strategy.

Regulatory and scientific alignment

Simulations Plus has highlighted its alignment with evolving regulatory expectations, including U.S. Food and Drug Administration draft guidance on streamlined nonclinical safety studies for certain biologics. Company statements describe how its validated engines and mechanistic modeling approaches support integrated weight‑of‑evidence assessments, PBPK, QST/QSP, and related methods that regulators expect for model‑informed decision‑making.

Published case studies referenced in company news demonstrate use of its platforms to combine PBPK and QST modeling to inform nonclinical strategies. The company also points to collaborations, such as work with the Institute of Medical Biology of the Polish Academy of Sciences, to validate AI‑driven drug design capabilities in ADMET Predictor®, including design and testing of novel ligands with favorable in vitro profiles.

Corporate governance and shareholder matters

Simulations Plus is incorporated in California and files periodic reports, proxy statements, and current reports with the U.S. Securities and Exchange Commission under file number 001‑32046. Its definitive proxy statement (DEF 14A) outlines matters such as the election of directors, ratification of the independent registered public accounting firm, and amendments to the company’s equity incentive plan. The company has also reported changes in its independent registered public accounting firm and executive employment agreements through Form 8‑K filings.

The company emphasizes Environmental, Social, and Governance (ESG) priorities in its communications, stating that it focuses ESG efforts where it believes they can have the most positive impact. References are made to ESG updates that describe initiatives and priorities in this area.

Stock information and investor focus

Simulations Plus common stock trades on Nasdaq under the symbol SLP. Investor‑oriented communications frequently include guidance ranges for revenue, software mix, adjusted EBITDA margin, and adjusted diluted earnings per share, as well as commentary on demand trends for software and services. The company also hosts conference calls, webcasts, and virtual Investor Day events to discuss its long‑term strategy, product roadmap, AI and cloud initiatives, and financial outlook.

For investors analyzing SLP, key themes from company disclosures include its dual software‑and‑services business model, emphasis on AI‑enabled biosimulation across the drug lifecycle, focus on regulatory‑aligned modeling approaches, and ongoing efforts to integrate platforms into a unified ecosystem for model‑informed drug development.